ReviewFrontiers in cardiovascular medicine2025
Dysfunctional high-density lipoprotein: an updated review.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Reconceptualizing Dyslipidemia: Diversity of Lipid Imbalances and Their Clinical Implications; A Narrative Review.Health science reports · 2026Article
- Micro- and Nanoplastics in Cardiovascular Toxicology: Human Tissue Detection, Clinical Phenotypes, and Adverse Outcome Signals.Cardiovascular toxicology · 2026Review
- Article
- Biology of HDL: From Structural Heterogeneity to Dysfunctional Remodeling in Cardiovascular Disease and Comorbidities.Antioxidants (Basel, Switzerland) · 2026Review
- Review
- Association of baseline and cumulative CHG index with risk of new-onset sarcopenia in middle-aged and older adults.The journal of nutrition, health & aging · 2026Article
- Lipid Disorders in Patients with Renal Failure: Role in Cardiovascular Events and Progression of Chronic Kidney Disease.Life (Basel, Switzerland) · 2026Review
- HDL-Associated Specific Paraoxonase-1 Activity Is Linked to Atherogenic Lipoprotein Measures in a High Cardiovascular Risk Population: A Cross-Sectional Study.Antioxidants (Basel, Switzerland) · 2026Article
- Physical Activity Modifies the Association Between Atherogenic Index of Plasma and New-Onset Diabetes in Middle-Aged and Older Adults.Healthcare (Basel, Switzerland) · 2026Article
- Oxidized High-Density Lipoprotein and Cardiovascular Risk in Rheumatoid Arthritis.Journal of clinical medicine research · 2026Article
- Machine learning evaluation of the discriminative ability of Castelli Risk Index-I and other non-traditional lipid indices for sarcopenia: a cross-sectional study based on CHARLS.Lipids in health and disease · 2026Article
- Associations of CALLY, CLR, and CHR with all-cause mortality in patients receiving maintenance hemodialysis: a two-center retrospective cohort study.Frontiers in endocrinology · 2026Article
- Cholesterol, high-density lipoprotein, and glucose (CHG) index and incident impaired fasting glucose in Chinese adults: a retrospective longitudinal cohort study.Frontiers in nutrition · 2026Article
- Carotid plaque formation prediction model and validation: a case-control study.Frontiers in cardiovascular medicine · 2026Article
- Associations between aggregate index of systemic inflammation and endometriosis risk utilizing logistic regression analysis.Frontiers in medicine · 2026Article
- Article
- Association between triglyceride-to-high-density lipoprotein cholesterol ratio and albuminuria in patients with type 2 diabetes: a cross-sectional study.Frontiers in nutrition · 2026Article
- Clinical and metabolic factors associated with response to postoperative radioactive iodine therapy in Chinese obese patients with papillary thyroid carcinoma.Frontiers in endocrinology · 2026Observational
- The correlation between the atherogenic index of plasma and aortic valve calcification in the general population: a retrospective observational cohort study.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-density lipoprotein (HDL) has earned its reputation as "good" cholesterol in cardiovascular health, primarily because of its strong inverse association with cardiovascular disease. A potential mechanism for this association is its ability to promote cholesterol efflux capacity (CEC) and consequently reduce the buildup of cholesterol in arterial plaque. However, recent research underscores the importance of not only maintaining high HDL cholesterol (HDL-C) levels but also ensuring the functionality and quality of HDL particles. HDL particles exhibit various other atheroprotective activities, including anti-inflammatory, antioxidant, and vasodilatory properties. Collectively, these functions are thought to contribute to reducing cardiovascular risk beyond mere cholesterol transport. Both acute and chronic inflammation can induce structural and functional changes in HDL, potentially rendering the particles pro-inflammatory. Factors that increase inflammation, such as lifestyle choices, autoimmune diseases, and oxidative stress, can adversely affect HDL functionality. Dysfunctional HDL, such as electronegative HDL H5 or HDL isolated from patients with cardiovascular disease (CVD), may lose its protective properties and even contribute to CVD progression by promoting inflammation, oxidative stress, and endothelial damage. Recent studies indicate that the CEC of HDL particles may serve as a more critical determinant of atheroprotection than the absolute concentration of HDL-C. This review emphasizes the need to focus on both quantity and quality of HDL to reduce cardiovascular risk more effectively. Understanding the mechanisms behind HDL's protective effects provide valuable insights into heart health and potential therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.